ORMP Oramed Pharmaceuticals Inc. - Common Stock
$4,83
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 10, 2026
52W-Spanne
$2–$5
89% of range
Analystenbewertung
HOLD
6 analysts
Kursziel
$6
+29% upside
P/E (TTM)
0.0
ROE
37.0%
Nettogewinnmarge
3202.5%
Über Oramed Pharmaceuticals Inc. - Common Stock Unternehmensübersicht von Wikipedia
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Mehr lesen
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge. The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset.
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
ORMP Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.83
Marktkapitalisierung
$197.7K
P/E (TTM)
0.0
EPS (TTM)
$1.50
Umsatz (TTM)
$2M
Dividendenrendite
—
ROE
37.0%
Verschuldungsgrad
—
52W-Spanne
$2 – $5
ORMP Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$2M
2017-08-31
→
2025-12-31
EPS
$1.50
2022-12-31
→
2025-12-31
Freier Cashflow
$-9M
2019-08-31
→
2025-12-31
Margen
3202.5%
2025-12-31
→
2025-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
ORMP
Peer-Median
P/E (TTM)
0.0
23.4
P/S (TTM) (K/V (TTM))
0.1
11.2
P/B (K/B)
0.0
2.5
Price / FCF (Kurs / FCF)
-0.0
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
ORMP
Peer-Median
Gross Margin (Bruttogewinnmarge)
0.65%
82.8%
Operating Margin (Betriebsgewinnmarge)
-754.4%
—
Net Profit Margin (Nettogewinnmarge)
3202.5%
-199.7%
ROA
33.2%
-34.8%
ROE
37.0%
-33.2%
ROIC
-6.4%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
ORMP
Peer-Median
Current Ratio (Liquiditätsgrad)
7.0
1.5
Quick Ratio
2.7
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
ORMP
Peer-Median
Revenue YoY (Umsatz YoY)
-50.4%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
-9.6%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
ORMP
Peer-Median
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite
—
Ausschüttungsquote
—
5J Div CAGR
—
| Ex-Datum | Betrag |
|---|---|
| 16. Januar 2026 | $0,2500 |
ORMP Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
VERKAUF
6 Analysten
- Starker Kauf 0 0,0%
- Kauf 0 0,0%
- Halten 3 50,0%
- Verkauf 1 16,7%
- Starker Verkauf 2 33,3%
12-Monats-Kursziel
1 Analysten · 2026-08-17
Tief
$6.25
Hoch
$6.25
Median-Ziel
$6.25
+29,4%
Mittelwert-Ziel
$6.25
+29,4%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.32%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. Dezember 2025 | $0.24 | $0.00 | 0.24% |
| 30. September 2025 | $1.12 | $-0.04 | 1.2% |
| 30. Juni 2025 | $0.31 | $-0.04 | 0.35% |
| 31. März 2025 | $-0.19 | $-0.01 | -0.18% |
| 31. Dezember 2024 | $0.00 | $-0.03 | 0.03% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| ORMP | $112M | 1.9 | -50.4% | 3202.5% | 37.0% | 0.65% |
| TTRX | $116M | -32.8 | — | — | -141.7% | — |
| ANTX | $31M | -1.0 | — | — | -57.7% | — |
| SIGA | $438M | 19.1 | -31.8% | 24.6% | 11.4% | — |
| DERM | — | -16.4 | 10.2% | -18.5% | -44.7% | — |
| LENZ | $502M | -5.6 | — | -430.2% | -33.5% | — |
| NRXP | — | — | — | — | — | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | · | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Cost of Revenue | $2M | · | · | · | · | · | $90.0K | $-86.0K | $187.0K | |
| Gross Profit | $13.0K | · | · | · | · | · | · | · | · | |
| R&D Expense | $6M | $6M | $9M | $28M | · | $10M | $14M | $12M | $10M | |
| SG&A Expense | $9M | $6M | $8M | $14M | · | $4M | $4M | $4M | $3M | |
| Operating Income | $-15M | $-13M | $-16M | $-41M | · | $-12M | $-15M | $-14M | $-11M | |
| Interest Expense | · | · | $2M | · | · | · | · | · | · | |
| Interest Income | · | · | $10.0K | · | · | · | · | · | · | |
| Other Non-op | $-606.0K | $-27.0K | $13.3K | $3M | · | · | · | · | · | |
| Pretax Income | $75M | $-16M | $5M | $-38M | · | $-12M | $-14M | $-13M | $-10M | |
| Income Tax | $11M | $3M | · | $100.0K | · | · | $300.0K | · | $400.0K | |
| Net Income | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| EPS (Basic) | $1.53 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| EPS (Diluted) | $1.50 | $-0.48 | $0.14 | $-0.94 | · | · | · | · | · | |
| Shares (Basic) | 41,402,997 | 40,850,446 | 40,315,068 | 38,997,649 | · | · | · | · | · | |
| Shares (Diluted) | 42,418,644 | 40,850,446 | 40,566,901 | 38,997,649 | · | · | · | · | · | |
| EBITDA | $-15M | · | $-16M | $-41M | · | $-12M | $-15M | · | · |
Bilanz 23
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46M | $54M | $9M | $40M | · | $19M | $3M | $5M | $4M | |
| Short-term Investments | $5M | $3M | · | · | $8M | $3M | · | $5M | · | |
| Prepaid Expense | $3M | $1M | $537.0K | $1M | · | $611.0K | $1M | $574.0K | · | |
| Current Assets | $133M | $143M | $163M | $157M | $148M | $41M | $33M | $31M | · | |
| PP&E (Net) | $586.0K | $698.0K | $873.0K | $815.0K | $388.0K | $99.0K | $24.0K | $17.0K | · | |
| Other Non-current Assets | $44.0K | $32.0K | $27.0K | · | · | · | · | · | · | |
| Total Assets | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Accounts Payable | $443.0K | $789.0K | $551.0K | $4M | $5M | $2M | $3M | $2M | · | |
| Accrued Liabilities | $1M | $402.0K | $605.0K | · | · | · | · | · | · | |
| Short-term Debt | $652.0K | $329.0K | $51M | · | · | · | $3M | $2M | · | |
| Current Liabilities | $19M | $6M | $53M | $6M | $7M | $5M | $5M | $5M | · | |
| Capital Leases | $540.0K | $156.0K | $342.0K | $647.0K | $370.0K | $31.0K | · | · | · | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | $60.0K | $63.0K | · | · | $211.0K | $271.0K | $313.0K | · | |
| Long-term Debt | · | · | · | $25.0K | $12M | · | $10M | $11M | · | |
| Total Debt | · | · | $51M | · | · | · | $3M | · | · | |
| Common Stock | $472.0K | $480.0K | $485.0K | $476.0K | $459.0K | $284.0K | $208.0K | $207.0K | · | |
| Paid-in Capital | · | · | · | $314M | $293M | $125M | · | · | · | |
| Retained Earnings | $-123M | $-177M | $-158M | $-163M | $-127M | $-93M | $-81M | $-69M | · | |
| AOCI | · | · | · | · | · | · | · | $702.0K | · | |
| Stockholders' Equity | $200M | $145M | $164M | $152M | $166M | $33M | $19M | $31M | $19M | |
| Liabilities + Equity | $231M | $155M | $221M | $162M | $178M | $45M | $35M | $47M | · | |
| Shares Outstanding | 39,275,006 | 39,920 | 40,339,000 | 39,564,000 | 38,158 | 23,675,530 | 17,383,359 | 17,369,875 | · |
Cashflow 12
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $4M | $4M | $12M | · | $465.0K | $808.0K | $2M | $2M | |
| Deferred Tax | $8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-9M | $-8M | $-10M | $-28M | · | $-12M | $-13M | $-15M | $-6M | |
| CapEx | $9.0K | $18.0K | $254.0K | $496.0K | · | $82.0K | $15.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $5M | $106M | $-73M | $30M | · | $5M | $11M | $-7M | $4M | |
| Stock Issued | · | · | $2M | $12M | · | · | · | · | · | |
| Stock Repurchased | $5M | $2M | · | · | · | · | · | · | · | |
| Net Stock Activity | $-5M | · | $2M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-5M | $-52M | $52M | $11M | · | $24M | · | $23M | $2M | |
| Net Change in Cash | $-8M | $45M | $-31M | $13M | · | $16M | $-2M | $1M | $62.0K | |
| Taxes Paid | · | $2M | · | $2M | · | · | $300.0K | · | $400.0K | |
| Free Cash Flow | $-9M | · | $-11M | $-28M | · | $-13M | $-13M | · | · |
Rentabilität 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.65% | · | · | · | · | · | · | · | · | |
| Operating Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| Net Margin | 3202.5% | · | 412.3% | -1397.1% | · | -424.8% | -531.1% | · | · | |
| Pretax Margin | 3766.2% | · | 379.7% | · | · | -424.8% | -520.0% | · | · | |
| EBITDA Margin | -754.4% | · | -1176.8% | -1502.0% | · | -433.8% | -541.3% | · | · | |
| ROA | 33.2% | · | 2.9% | -22.2% | · | -29.0% | -35.0% | · | · | |
| ROE | 37.0% | · | 3.5% | -23.7% | · | -47.0% | -70.1% | · | · | |
| ROIC | -6.4% | · | · | · | · | · | -67.6% | · | · |
Liquidität & Solvenz 4
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.0 | · | 3.1 | 27.3 | · | 8.9 | 6.3 | · | · | |
| Quick Ratio | 2.7 | · | 1.3 | 0.7 | · | 5.0 | 1.3 | · | · | |
| Debt / Equity | · | · | 0.3 | · | · | · | 0.1 | · | · | |
| Interest Coverage | · | · | -7.7 | · | · | · | · | · | · |
Effizienz 1
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | · | 0.1 | 0.1 | · | · |
Wachstumsraten 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -50.4% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -9.6% | · | · | · | · | · | · | · | · |
Bewertung (TTM) 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $3M | $1M | $3M | · | $3M | $3M | $2M | $2M | |
| Net Income TTM | $64M | $-19M | $5M | $-37M | · | $-12M | $-14M | $-13M | $-10M | |
| Market Cap | $112M | · | $93M | $476M | · | $83M | $58M | · | · | |
| Enterprise Value | · | · | $77M | · | · | · | $53M | · | · | |
| P/E | 1.9 | -5.0 | 16.5 | -12.8 | · | · | · | · | · | |
| P/S | 56.0 | · | 69.5 | 176.1 | · | 30.5 | 21.4 | · | · | |
| P/B | 0.6 | · | 0.6 | 3.1 | · | 2.5 | 3.0 | · | · | |
| P / Tangible Book | 0.6 | 0.7 | 0.6 | 3.1 | · | 2.5 | · | · | · | |
| P / Cash Flow | -12.2 | · | -9.1 | -17.0 | · | -6.6 | -4.5 | · | · | |
| P / FCF | -12.2 | · | -8.8 | -16.8 | · | -6.6 | -4.5 | · | · | |
| EV / EBITDA | · | · | -4.9 | · | · | · | -3.6 | · | · | |
| EV / FCF | · | · | -7.3 | · | · | · | -4.1 | · | · | |
| EV / Revenue | · | · | 57.8 | · | · | · | 19.8 | · | · | |
| Earnings Yield | 52.6% | -19.8% | 6.1% | -7.8% | · | · | · | · | · |
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | · | · | $2M | · | · | · | · | $0 | · | $674.0K | $666.0K | $681.0K | $682.0K | |
| Cost of Revenue | · | · | $0 | · | · | $2M | · | · | · | · | · | · | · | · | · | · | |
| Gross Profit | · | · | $0 | · | · | $13.0K | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | · | $2M | $2M | $1M | $1M | $2M | $1M | $2M | $1M | $1M | $2M | $957.0K | $2M | $4M | $7M | $5M | |
| SG&A Expense | $3M | $2M | $4M | $1M | $1M | $2M | $2M | $847.0K | $2M | $2M | $2M | $3M | $2M | $1M | $3M | $3M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $11.0K | |
| Operating Income | $-3M | $-4M | $-6M | $-2M | $-2M | $-4M | $-4M | $-3M | $-3M | $-3M | $-4M | $-3M | $-4M | $-5M | $-10M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $592.0K | · | $826.0K | · | · | · | · | |
| Other Non-op | $-4.0K | $-100.0K | $-74M | $61M | · | $-143.0K | $-2M | $-15M | $14M | $4M | $-4M | $435.0K | $2M | $2M | $1M | $1M | |
| Pretax Income | $102M | $49M | $10M | $59M | $13M | $-7M | $-10M | $-19M | $11M | $2M | $13M | $-3M | $-1M | · | $-9M | $-7M | |
| Income Tax | $23M | $11M | $-212.0K | $11M | $-126.0K | $584.0K | $416.0K | $1M | $2M | · | · | · | · | · | $0 | $100.0K | |
| Net Income | $78M | $38M | $10M | $48M | $13M | $-8M | $-10M | $-20M | $9M | $2M | $13M | $-3M | $-1M | $-3M | $-8M | $-7M | |
| EPS (Basic) | $1.90 | $0.94 | $0.24 | $1.16 | $0.32 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| EPS (Diluted) | $1.84 | $0.91 | $0.25 | $1.13 | $0.31 | $-0.19 | $-0.26 | $-0.48 | $0.22 | $0.04 | $0.33 | $-0.08 | $-0.03 | $-0.08 | $-1.66 | $0.18 | |
| Shares (Basic) | 41,040,479 | 40,773,866 | -83,325,572 | 41,756,301 | 41,743,486 | 41,228,782 | -81,842,111 | 40,896,845 | 40,959,759 | 40,835,953 | -80,397,680 | 40,445,896 | 40,225,594 | 40,041,258 | -77,577,522 | 39,100,231 | |
| Shares (Diluted) | 42,501,252 | 41,970,186 | -84,194,067 | 42,774,504 | 42,609,425 | 41,228,782 | -83,201,413 | 40,896,845 | 41,591,007 | 41,564,007 | -80,145,847 | 40,445,896 | 40,225,594 | 40,041,258 | -77,577,522 | 39,100,231 | |
| EBITDA | $-3M | $-4M | · | $-2M | $-2M | $-4M | · | $-3M | $-3M | $-3M | · | $-3M | $-4M | $-5M | · | $-8M |
Bilanz 22
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $13M | $46M | $52M | $16M | · | $54M | · | $10M | $19M | · | · | · | · | $40M | · | |
| Short-term Investments | $846.0K | $5M | $5M | $5M | $2M | $4M | $3M | $57M | $66M | $78M | · | $49.4K | $943.0K | $2M | · | $5M | |
| Prepaid Expense | $2M | $2M | $3M | $1M | $1M | $832.0K | $1M | $474.0K | $533.0K | $501.0K | $537.0K | $666.0K | $769.0K | · | $1M | · | |
| Current Assets | $53M | $68M | $133M | $136M | $99M | $131M | $143M | $143M | $153M | $177M | $163M | $176M | $151M | $155M | $157M | $160M | |
| PP&E (Net) | $532.0K | $561.0K | $586.0K | $614.0K | $645.0K | $671.0K | $698.0K | $718.0K | $765.0K | $819.0K | $873.0K | $923.0K | $945.0K | $977.0K | $815.0K | $535.0K | |
| Other Non-current Assets | $49.0K | $46.0K | $44.0K | $40.0K | $38.0K | $32.0K | $32.0K | · | · | · | $27.0K | · | · | · | · | · | |
| Total Assets | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Accounts Payable | $374.0K | $481.0K | $443.0K | $560.0K | $715.0K | $509.0K | $789.0K | $5M | $3M | $1M | $551.0K | $3M | $828.0K | $4M | $4M | $4M | |
| Accrued Liabilities | $1M | $1M | $1M | $585.0K | $841.0K | $800.0K | $402.0K | · | · | · | $605.0K | · | · | · | · | · | |
| Short-term Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | $51M | $75M | $3.0K | $1.0K | · | · | |
| Current Liabilities | $11M | $11M | $19M | $6M | $4M | $5M | $6M | $5M | $4M | $34M | $53M | $78M | $1M | $5M | $6M | $7M | |
| Capital Leases | $484.0K | $493.0K | $540.0K | $589.0K | $648.0K | $120.0K | $156.0K | $186.0K | $236.0K | $272.0K | $342.0K | $389.0K | $488.0K | $564.0K | $647.0K | $672.0K | |
| Deferred Tax | $40M | $18M | $8M | $8M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $60.0K | $60.0K | $60.0K | · | $63.0K | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $75M | · | · | · | $5M | |
| Total Debt | · | · | · | $1.0K | $34.0K | $36.0K | · | · | · | $32M | · | $75M | $3.0K | $1.0K | · | · | |
| Common Stock | $495.0K | $491.0K | $472.0K | $490.0K | $491.0K | $491.0K | $480.0K | $484.0K | $488.0K | $487.0K | $485.0K | $484.0K | $484.0K | $481.0K | $476.0K | $470.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | · | $319M | $317M | · | $308M | |
| Retained Earnings | $-7M | $-85M | $-123M | $-123M | $-171M | $-184M | $-177M | $-166M | $-147M | $-156M | $-158M | $-171M | $-168M | $-166M | $-163M | $-155M | |
| Stockholders' Equity | $317M | $238M | $200M | $203M | $155M | $141M | $146M | $156M | $177M | $167M | $164M | $149M | $152M | $151M | $152M | $154M | |
| Liabilities + Equity | $370M | $269M | $231M | $220M | $162M | $148M | $155M | $165M | $184M | $204M | $221M | $231M | $156M | $160M | $162M | $164M | |
| Shares Outstanding | 41,314,211 | 40,926,081 | 39,275,006 | 40,838,226 | 40,845,087 | 40,850,455 | 39,919,545 | 40,209,575 | 40,628,924 | 40,519,160 | 40,338,979 | 40,282,688 | 40,219,396 | 39,969,979 | 39,563,888 | 39,113,236 |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $2M | $2M | $719.0K | $800.0K | $2M | $1M | $301.0K | $1M | $1M | $1M | $852.0K | $2M | $173.0K | $3M | $3M | |
| Deferred Tax | $22M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-200.0K | $-3M | $-466.0K | $-2M | $-4M | $-4M | $-2M | $-7M | $2M | $-1M | $-1M | $-694.0K | $-3M | $-6M | $-8M | $-2M | |
| CapEx | $2.0K | $5.0K | $2.0K | $0 | $4.0K | $3.0K | $11.0K | $5.0K | $0 | $2.0K | $3.0K | $32.0K | $20.0K | $199.0K | $308.0K | $121.0K | |
| Investing Cash Flow | $4M | $-19M | $-2M | $38M | $-55M | $24M | $15M | $-34M | $95M | $30M | $30M | $-75M | $-15M | $-13M | $11M | $1M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $-2.0K | $0 | $2M | $4M | $-3M | |
| Stock Repurchased | · | · | $4M | $361.0K | · | · | $1M | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | $78.0K | $10M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-2M | $-10M | $-4M | $-361.0K | · | · | $-1M | $-1M | $-31M | $-19M | $-25M | $75M | $0 | $2M | $4M | $4M | |
| Net Change in Cash | $2M | $-33M | $-6M | $36M | $-59M | $20M | $12M | $-43M | $66M | $10M | $4M | $-1M | $-17M | $-16M | $7M | $3M | |
| Taxes Paid | · | · | · | $-7M | · | · | · | · | · | · | · | $527.0K | $3M | $308.0K | · | $167.0K | |
| Free Cash Flow | · | $-3M | · | · | · | $-4M | · | · | · | $-1M | · | · | · | $-6M | · | · |
Rentabilität 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 0.65% | · | · | · | · | · | · | · | · | · | · | |
| Operating Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| Net Margin | · | · | · | · | · | -382.1% | · | · | · | · | · | · | -177.2% | -542.2% | · | -1063.5% | |
| Pretax Margin | · | · | · | · | · | -352.9% | · | · | · | · | · | · | · | · | · | -1048.8% | |
| EBITDA Margin | · | · | · | · | · | -225.0% | · | · | · | · | · | · | -562.5% | -782.0% | · | -1200.7% | |
| ROA | 29.4% | 18.4% | · | 25.1% | 7.7% | -4.3% | · | -9.9% | 5.4% | 0.85% | · | -1.6% | -0.75% | -2.2% | · | -5.9% | |
| ROE | 33.1% | 20.2% | · | 26.9% | 8.0% | -5.0% | · | -12.8% | 5.6% | 0.97% | · | -2.1% | -0.78% | -2.3% | · | -6.5% | |
| ROIC | -0.67% | -1.2% | · | -0.97% | -1.6% | -3.5% | · | -2.1% | -1.5% | · | · | · | · | · | · | -5.4% |
Liquidität & Solvenz 4
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 6.5 | · | 22.2 | 26.8 | 23.9 | · | 27.1 | 41.1 | 5.3 | · | 2.2 | 141.5 | 31.2 | · | 24.5 | |
| Quick Ratio | 1.5 | 1.7 | · | 9.3 | 4.8 | 0.7 | · | 10.9 | 20.4 | 2.9 | · | 0.0 | 0.9 | 0.5 | · | 0.8 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.2 | · | 0.5 | 0.0 | 0.0 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -5.0 | · | -3.5 | · | · | · | · |
Effizienz 1
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | · | 0.0 | 0.0 | · | 0.0 |
Bewertung (TTM) 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Net Income TTM | $178M | $92M | · | $34M | $-5M | $-17M | · | $-12M | $6M | $-6M | · | $-15M | $-22M | $-32M | · | $-36M | |
| Market Cap | $199M | $139M | · | $108M | $92M | $87M | · | $98M | $104M | $118M | · | $105M | $144M | $87M | · | $253M | |
| Enterprise Value | · | · | · | $51M | $74M | · | · | · | · | $54M | · | · | · | · | · | · | |
| P/E | 1.1 | 1.6 | · | 3.4 | -16.1 | -5.2 | · | -8.1 | 17.1 | -19.5 | · | -261.0 | 10.5 | 3.4 | · | 7.0 | |
| P/S | · | · | · | · | · | · | · | 36.4 | 38.7 | 43.9 | · | 39.0 | 53.4 | 32.4 | · | 94.0 | |
| P/B | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Tangible Book | 0.6 | 0.6 | · | 0.5 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.7 | 1.0 | 0.6 | · | 1.6 | |
| P / Cash Flow | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.2 | · | · | · | -15.7 | · | · | |
| P / FCF | · | -47.7 | · | · | · | -24.8 | · | · | · | -80.1 | · | · | · | -15.2 | · | · | |
| EV / EBITDA | · | · | · | -20.9 | -29.9 | · | · | · | · | -18.2 | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -36.6 | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | 20.0 | · | · | · | · | · | · | |
| Earnings Yield | 87.1% | 63.5% | · | 29.2% | -6.2% | -19.2% | · | -12.3% | 5.8% | -5.1% | · | -0.38% | 9.5% | 29.4% | · | 14.3% | |
| Payout Ratio | · | 27.1% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $2M | — | $1M | $3M | — |
| Bruttogewinnmarge % | 0.65% | — | — | — | — |
| Betriebsgewinnmarge % | -754.4% | — | -1176.8% | -1502.0% | — |
| Nettoergebnis | $64M | $-19M | $5M | $-37M | — |
| Verwässerte EPS | $1.50 | $-0.48 | $0.14 | $-0.94 | — |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | — | — | 0.3 | — | — |
| Liquiditätsgrad | 7.0 | — | 3.1 | 27.3 | — |
| Quick Ratio | 2.7 | — | 1.3 | 0.7 | — |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-9M | — | $-11M | $-28M | — |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 88 Einreicher · $64.4M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 30 (+13 vs. Vorquartal) | 8 (0 vs. Vorquartal) | 19 (-1 vs. Vorquartal) | 19 (+5 vs. Vorquartal) | -209K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Aquamarine Financial (Cayman) Ltd | $12.083.562 | 2.512.175 | 18,77% | Aktien |
| Gem Investment Advisors, LLC | $9.614.238 | 1.998.802 | 14,94% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $9.189.697 | 1.910.540 | 14,28% | Aktien |
| Murchinson Ltd. | $6.206.314 | 1.290.294 | 9,64% | Aktien |
| SB Capital Management Inc | $5.415.000 | 1.900.000 | 8,41% | Aktien |
| BML Capital Management, LLC | $4.166.754 | 866.269 | 6,47% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.783.249 | 578.638 | 4,32% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $2.162.008 | 449.482 | 3,36% | Aktien |
| STATE STREET CORP | $1.164.501 | 242.100 | 1,81% | Aktien |
| Rathbones Group PLC | $1.120.816 | 233.018 | 1,74% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.105.732 | 229.882 | 1,72% | Aktien |
| GOLDMAN SACHS GROUP INC | $950.908 | 197.694 | 1,48% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $884.078 | 183.800 | 1,37% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $784.896 | 163.180 | 1,22% | Aktien |
| STRS OHIO | $643.578 | 133.800 | 1,00% | Aktien |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $495.247 | 102.962 | 0,77% | Aktien |
| JANE STREET GROUP, LLC | $470.606 | 97.839 | 0,73% | Aktien |
| Hillsdale Investment Management Inc. | $429.533 | 89.300 | 0,67% | Aktien |
| RITHOLTZ WEALTH MANAGEMENT | $405.709 | 84.347 | 0,63% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $402.280 | 83.634 | 0,63% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $287.518 | 59.775 | 0,45% | Aktien |
| XTX Topco Ltd | $240.130 | 49.923 | 0,37% | Aktien |
| Nuveen, LLC | $223.203 | 46.404 | 0,35% | Aktien |
| DEUTSCHE BANK AG\ | $159.682 | 33.198 | 0,25% | Aktien |
| PRELUDE CAPITAL MANAGEMENT, LLC | $157.350 | 32.713 | 0,24% | Aktien |
| BAILARD, INC. | $156.219 | 32.478 | 0,24% | Aktien |
| RHUMBLINE ADVISERS | $147.281 | 30.621 | 0,23% | Aktien |
| Bank of New York Mellon Corp | $143.016 | 29.733 | 0,22% | Aktien |
| ALGERT GLOBAL LLC | $139.288 | 28.958 | 0,22% | Aktien |
| WELLS FARGO & COMPANY/MN | $137.080 | 28.499 | 0,21% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $121.246 | 25.207 | 0,19% | Aktien |
| CITADEL ADVISORS LLC | $120.250 | 25.000 | 0,19% | Kaufoption |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $107.263 | 22.300 | 0,17% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $105.151 | 21.861 | 0,16% | Aktien |
| PNC Financial Services Group, Inc. | $101.972 | 21.200 | 0,16% | Aktien |
| Redwood Family Wealth LLC | $99.783 | 20.745 | 0,16% | Aktien |
| BANK OF AMERICA CORP /DE/ | $91.621 | 19.048 | 0,14% | Aktien |
| MORGAN STANLEY | $87.994 | 18.294 | 0,14% | Aktien |
| Sage Capital Management, LLC | $86.474 | 17.977 | 0,13% | Aktien |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $75.378 | 15.671 | 0,12% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $67.811 | 14.098 | 0,11% | Aktien |
| CITIGROUP INC | $66.590 | 13.844 | 0,10% | Aktien |
| JPMORGAN CHASE & CO | $65.461 | 14.108 | 0,10% | Aktien |
| Invesco Ltd. | $65.272 | 13.570 | 0,10% | Aktien |
| Y-Intercept (Hong Kong) Ltd | $61.650 | 12.817 | 0,10% | Aktien |
| Engineers Gate Manager LP | $61.077 | 12.698 | 0,09% | Aktien |
| Altshuler Shaham Ltd | $53.925 | 11.211 | 0,08% | Aktien |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $52.096 | 12.895 | 0,08% | Aktien |
| Glass Jacobson Investment Advisors llc | $50.698 | 10.540 | 0,08% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $50.115 | 10.419 | 0,08% | Aktien |
| MARSHALL WACE, LLP | $50.024 | 10.400 | 0,08% | Aktien |
| Hudson Bay Capital Management LP | $49.375 | 10.265 | 0,08% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $47.706 | 9.918 | 0,07% | Aktien |
| Steward Partners Investment Advisory, LLC | $42.453 | 8.826 | 0,07% | Aktien |
| BARCLAYS PLC | $27.917 | 5.804 | 0,04% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $25.974 | 5.400 | 0,04% | Aktien |
| NORTHERN TRUST CORP | $25.503 | 5.302 | 0,04% | Aktien |
| Tower Research Capital LLC (TRC) | $23.218 | 4.827 | 0,04% | Aktien |
| OSAIC HOLDINGS, INC. | $20.283 | 4.217 | 0,03% | Aktien |
| FEDERATED HERMES, INC. | $19.221 | 3.996 | 0,03% | Aktien |
| N.E.W. Advisory Services LLC | $16.495 | 3.429 | 0,03% | Aktien |
| Legal & General Group Plc | $15.979 | 3.322 | 0,02% | Aktien |
| CITADEL ADVISORS LLC | $15.565 | 3.236 | 0,02% | Aktien |
| Ameritas Investment Partners, Inc. | $14.853 | 3.088 | 0,02% | Aktien |
| HUNTINGTON NATIONAL BANK | $14.440 | 3.002 | 0,02% | Aktien |
| Pioneer Family Office, LLC | $14.430 | 3.000 | 0,02% | Aktien |
| Russell Investments Group, Ltd. | $13.088 | 2.721 | 0,02% | Aktien |
| UBS Group AG | $12.987 | 2.700 | 0,02% | Aktien |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | $7.576 | 1.575 | 0,01% | Aktien |
| MetLife Investment Management, LLC | $7.037 | 1.463 | 0,01% | Aktien |
| BlackRock, Inc. | $6.768 | 1.407 | 0,01% | Aktien |
| ROYAL BANK OF CANADA | $6.000 | 1.246 | 0,01% | Aktien |
| MCF Advisors LLC | $5.162 | 1.073 | 0,01% | Aktien |
| Caitlin John, LLC | $4.810 | 1.000 | 0,01% | Aktien |
| McIlrath & Eck, LLC | $3.400 | 1.000 | 0,01% | Aktien |
| Sterling Capital Management LLC | $3.300 | 686 | 0,01% | Aktien |
| IFP Advisors, Inc | $2.405 | 500 | 0,00% | Aktien |
| PROEQUITIES, INC. | $2.310 | 1.000 | 0,00% | Aktien |
| Golden State Wealth Management, LLC | $1.458 | 303 | 0,00% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $999 | 214 | 0,00% | Aktien |
| HRT FINANCIAL LP | $469 | 97.582 | 0,00% | Aktien |
| FMR LLC | $332 | 69 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $284 | 59 | 0,00% | Aktien |
| PRICE T ROWE ASSOCIATES INC /MD/ | $135 | 27.909 | 0,00% | Aktien |
| TrinityBridge Ltd | $56 | 11.675 | 0,00% | Aktien |
| HARBOUR INVESTMENTS, INC. | $48 | 10 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $29 | 6 | 0,00% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $8 | 1.691 | 0,00% | Aktien |
Unternehmensinsider 30 Insider · 13 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Nadav Kidron | President and CEO | 30. März 2026 F | 3.422.243 | 0 | 0 | $0 |
| Avraham Gabay | Chief Financial Officer | 1. Juli 2026 S | 671.785 | 0 | 1 | $-330.854 |
| David Silberman | Chief Financial Officer | 4. Januar 2024 A | 366.500 | 0 | 0 | $0 |
| Hilla Eisenberg | CFO, Treasurer and Secretary | 26. Februar 2019 A | — | 0 | 0 | $0 |
| Yifat Hen Zommer | CFO, Treasurer and Secretary | 30. Juni 2017 A | 46.560 | 0 | 0 | $0 |
| Chaime Orlev | CFO, Treasurer and Secretary | 12. Oktober 2008 A | — | 0 | 0 | $0 |
| Joshua Hexter | COO & CBO | 2. Juli 2026 M | 1.073.384 | 0 | 1 | $-611.020 |
| Miriam Kidron | Chief Scientific Officer | 30. März 2026 F | 1.133.138 | 0 | 0 | $0 |
| Netanel Derovan | Chief Legal Officer | 26. Mai 2023 A | 149.500 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3. Januar 2023 S | 126.143 | 0 | 0 | $0 |
| Michael Rabinowitz | Chief Commercial Officer | 3. Januar 2022 A | 109.468 | 0 | 0 | $0 |
| Mark Daniel Hasleton | VP Business Development | 26. Februar 2019 A | — | 0 | 0 | $0 |
| Ronald Edward Law | Chief Strategy Officer | 20. März 2017 A | — | 0 | 0 | $0 |
| Yehuda Reznick | Direktor | 31. Dezember 2025 A | 105.180 | 0 | 0 | $0 |
| Daniel Aghion | Direktor | 31. Dezember 2025 A | 113.441 | 0 | 0 | $0 |
| Benjamin Shapiro | Direktor | 31. Dezember 2025 A | 123.220 | 0 | 0 | $0 |
| Arie Mayer | Direktor | 31. Dezember 2025 A | 168.009 | 0 | 0 | $0 |
| Leonard Sank | Direktor | 5. Juni 2025 A | 134.531 | 0 | 0 | $0 |
| Yadin Rozov | Direktor | 4. Januar 2024 A | 155.320 | 0 | 0 | $0 |
| Kevin Rakin | Direktor | 21. März 2022 S | 46.661 | 0 | 0 | $0 |
| Aviad Friedman | Direktor | 3. Januar 2022 G | 0 | 0 | 0 | $0 |
| Gao Xiaoming | Direktor | 8. Januar 2020 A | — | 0 | 0 | $0 |
| David Mark Slager | Direktor | 15. April 2019 A | 1.316.328 | 0 | 0 | $0 |
| Xiaopeng Li | Direktor | 2. August 2017 P | 206.350 | 0 | 0 | $0 |
| Harold Jacob | Direktor | 10. März 2016 S | 16.396 | 0 | 0 | $0 |
| Michael Berelowitz | Direktor | 9. Dezember 2015 S | 22.896 | 0 | 0 | $0 |
| Gerald M Ostrov | Direktor | 23. Februar 2015 A | 24.896 | 0 | 0 | $0 |
| REGALS CAPITAL MANAGEMENT LP | 10%-Eigentümer | 23. Dezember 2015 X | 1.186.823 | 0 | 0 | $0 |
| Zeev Bronfeld | 10%-Eigentümer | 27. September 2011 S | 5.808.517 | 0 | 0 | $0 |
| Michael Young | — | 27. Mai 2004 S | 0 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 9 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. | 22. Juli 2026 | 3,30% | Änderung | — | SEC |
| Nadav Kidron ×8 Einreichungen | 28. August 2025 | 7,60% | Änderung | — | SEC |
| Regals Capital Management LP, Regals Fund LP, David M. Slager ×2 Einreichungen | 20. Juli 2018 | — | Erste Einreichung | — | SEC |
| Hefei Tianhui Incubator of Technologies Co., Ltd | 6. Januar 2016 | — | Erste Einreichung | — | SEC |
| Leonard Sank | 15. Dezember 2014 | — | Erste Einreichung | Passive Anlage | SEC |
| Miriam Kidron ×2 Einreichungen | 3. Februar 2014 | — | Erste Einreichung | — | SEC |
| Zeev Bronfeld | 6. März 2006 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Juni 2004 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Juni 2004 | — | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 14 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,03% | 114.970 SH | 8. August 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 7.046 SH | 8. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29.637 SH | 8. August 2026 | Täglich |
| IWN · iShares Trust | 0,01% | 315.439 SH | 8. August 2026 | Täglich |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 28.155 NS | 31. Mai 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 621.705 SH | 8. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,00% | 26.896 NS | 30. April 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 4.523 NS | 30. April 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.536 NS | 30. April 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,00% | 4.152 NS | 31. Mai 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 3.431 NS | 30. April 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 196.765 SH | 8. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.480 SH | 8. August 2026 | Täglich |
| DXUV · Dimensional ETF Trust | 0,00% | 4 NS | 30. April 2026 | N-PORT |